Zeta CD5 Antibody. Zeta’s recombinant mouse antibody recognizes CD5, which is found on 95% of thymocytes and 72% of peripheral blood lymphocytes. In lymph nodes, CD5 is expressed in T cell areas. CD5 is a 67kDa transmembrane protein. CD5 is a pan T-cell marker that also reacts with a range of neoplastic B-cells, e.g. chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, and a subset (~10%) of diffuse large B-cell lymphoma. CD5 aberrant expression is useful in making a diagnosis of mature T-cell neoplasms. The CD5 antibody detection is diagnostic in CLL/SLL within a panel of other B-cell markers, especially one that includes anti-CD23. The CD5 antibody is also very useful in differentiating among mature small lymphoid cell malignancies. In addition, the antibody to CD5 can be used in distinguishing thymic carcinoma (+) from thymoma (-). The CD5 antibody does not react with granulocytes or monocytes.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.